Insider Purchase: Peter Altman Acquires 100 BioCardia Shares at $1.83

Rhea-AI Filing Summary

Peter Altman, who is listed as both President and CEO and a director of BioCardia, Inc., purchased 100 shares of the company’s common stock on 08/13/2025 at a price of $1.83 per share. The filing states the transaction was executed in a single trade and is reported on a Form 4.

Following the purchase, Altman is reported to beneficially own 168,062 shares directly. The Form 4 was signed on 08/13/2025 by David McClung by power of attorney. The form indicates it was filed by one reporting person and confirms Altman’s dual role as officer and director.

Positive

• Insider purchase disclosed: Peter Altman acquired 100 shares at $1.83, a transparent insider transaction reported on Form 4.
• Clear post-transaction ownership: Filing reports Altman directly holds 168,062 shares after the purchase.

Negative

• None.

Insights

Securities Analyst

TL;DR: CEO/director bought 100 shares at $1.83, raising direct holdings to 168,062; trade was a single execution.

The transaction is a straightforward insider purchase reported on Form 4. The size—100 shares at $1.83—represents a modest incremental acquisition relative to the reported direct holdings of 168,062 shares. The filing is signed by an attorney-in-fact, indicating the report was timely executed on the transaction date. For investors, this is a factual disclosure of insider activity without additional operational or financial data in the filing.

Corporate Governance Expert

TL;DR: Insider purchase by the company’s President and CEO is disclosed; filing shows standard reporting mechanics.

The Form 4 documents a compliant disclosure: the reporting person is identified with title and address, the transaction date, price, and post-transaction beneficial ownership are provided, and the form bears a signature by power of attorney. The record notes both director and officer checkboxes were marked, confirming Altman’s roles. This filing supplies necessary transparency about insider holdings but provides no governance actions or related-party arrangements beyond the purchase itself.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Altman Peter

(Last) (First) (Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE CA 94085

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/13/2025		P		100(1)	A	$1.83(1)	168,062	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in a single trade.

	/s/ David McClung, by power of attorney	08/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Peter Altman report on Form 4 for BioCardia (BCDA)?

The Form 4 reports a purchase of 100 shares of BioCardia common stock on 08/13/2025 at a price of $1.83 per share.

How many BioCardia shares does Altman beneficially own after the transaction?

After the reported purchase, Altman is shown to beneficially own 168,062 shares directly.

Who signed the Form 4 for this transaction?

The Form 4 is signed by David McClung by power of attorney on 08/13/2025.

What role does the reporting person hold at BioCardia according to the filing?

The filing indicates the reporting person, Peter Altman, is both a Director and the President and CEO of BioCardia.

Was the purchase executed in multiple trades or a single trade?

The filing explicitly states the transaction was executed in a single trade.